| Name | Title | Contact Details |
|---|---|---|
Jill Mooney |
Senior Vice President of Research and Development | Profile |
Mitchell Finer |
President Research and Development | Profile |
Missy Kotchey |
Director of People Operations and Chief of Staff | Profile |
ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.
At Nizhoni Health, we believe that quality of care and quality of staff go hand-in-hand. Our highly trained staff consists of qualified, experienced nurses and clinical specialists. Our nurses have worked in a variety of clinical settings including the major teaching hospitals within the metropolitan area. Nizhoni Health is a Medicare/Medicaid certified home health agency. Our enduring goal is to provide an effective alternative to inpatient hospitalization and assist clients in making the transition to the community. All clients are treated with dignity and respect.
Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases.
Pareto Biotechnologies has pioneered development of a revolutionary synthetic biology platform that produces naturally derived, high value “designer molecules.” Pareto’s technology is the result of over a decade of academic and private sector research and intellectual property focused on one particular polyketide pathway. Building on Dr. Joe Noel’s groundbreaking research at the Salk Institute, this pathway – previously dismissed as the “poor man’s pathway” – is the foundation of Pareto’s platform, capable of generating known products and novel molecules. In the near term, Pareto will introduce “designer molecules” as cosmetics, flavors and fragrances including molecules with properties unlike anything previously experienced. In the long term, Pareto’s molecules will be designed to enhance nutraceuticals, pharmaceuticals, and industrial commodities. Pareto’s potential is limitless. Join us as we ignite a molecular revolution
Totient is an AI-driven biotechnology company leveraging tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics.